Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BBT-877 in Idiopathic Pulmonary Fibrosis
NCT05483907Phase 2Completed
- Sponsor
- Bridge Biotherapeutics
- Start
- Apr 2023
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of LCB17-0877 in idiopathic pulmonary fibrosis (IPF), sponsored by Bridge Biotherapeutics. Started Apr 2023; status: completed.
02
Drugs
LCB17-0877
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT05483907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05483907.